Why Perfusion Quality Is a Margin Lever, Not a Commodity

Hospitals tend to treat perfusion as a commodity input: a service to be purchased at the lowest defensible price. That framing made sense under fee-for-service. Under bundled payments, readmission penalties, and complication-based scrutiny, it no longer does.

Complications are the real cost center

The largest financial swings in a cardiac case are not supplies or labor — they are complications. Acute kidney injury, stroke, prolonged ventilation, and reoperation for bleeding can each add days of ICU stay and tens of thousands of dollars, and several are tracked in public quality reporting. When a bundle sets the payment, every avoided complication falls to the bottom line.

Where perfusion touches outcomes

Goal-directed perfusion — maintaining adequate oxygen delivery on bypass, limiting hemodilution, managing temperature and glucose — is associated in the literature with reduced organ injury, particularly acute kidney injury. Perfusion also governs the transfusion practices tied to infection and length of stay. None of this makes perfusion the sole determinant of outcome, but it makes it a genuine and controllable input.

The strategic error of buying on price alone

The administrator's reframe

The right question is not "what is the cheapest way to cover our cases?" It is "what perfusion practice produces the best total cost of care?" Those are different questions with different answers — and only the second one aligns with how your program is actually paid.